Skip to main content
SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD logo

SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002737 ISIN · CNE100001WT7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,262 across all filing types
Latest filing 2023-10-23 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002737

About SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD

https://www.kuihuayaoye.com

Sunflower Pharmaceutical Group Co., Ltd. focuses on the research, development, manufacturing, and distribution of proprietary Chinese medicines, chemical drugs, and health supplements. The organization is particularly noted for its specialization in pediatric medicine, marketed under the "Little Sunflower" brand, which includes treatments for respiratory and digestive ailments. Its extensive product portfolio also covers gynecological health and general internal medicine. The group operates several integrated production bases and research institutes, facilitating a comprehensive approach to drug formulation and quality control. By leveraging a robust supply chain and a wide-reaching distribution network, the company provides a diverse range of over-the-counter and prescription solutions aimed at improving family health and wellness.

Recent filings

Filing Released Lang Actions
关于磷酸奥司他韦干混悬剂获得上市许可受理的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from a company regarding the acceptance of a drug registration application by the National Medical Products Administration. It contains no financial data, no report or financial statements, and is not a meeting material or voting result. It is an official regulatory announcement about a product approval process. The document length is short (871 characters) and it is clearly an announcement of a regulatory event rather than a report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS).
2023-10-23 Chinese
关于布洛芬混悬滴剂获得上市许可受理的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (830 characters) from a company about receiving a regulatory acceptance notice for a drug registration application from the National Medical Products Administration. It includes basic drug information, risk warnings about the approval process, and a statement that the company will continue to disclose updates. There are no financial statements, no detailed financial data, no management discussion, or other report content. The document is an official announcement of a regulatory event related to product approval, not a financial report or detailed filing. It fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other categories.
2023-10-11 Chinese
关于收购海南惠海医药有限公司的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the progress of an acquisition by the company 葵花药业集团股份有限公司. It details the completion of the equity transfer and the issuance of a new business license for the acquired company. The document is short (1179 characters) and focuses on the update of a specific transaction rather than providing comprehensive financial data or detailed analysis. It does not contain financial statements or detailed management discussion. Therefore, it is best classified as a Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as acquisitions.
2023-10-08 Chinese
关于使用闲置自有资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company (葵花药业集团股份有限公司) regarding the progress of using idle self-owned funds for cash management. It details the amounts invested, types of financial products purchased, risk control measures, and the impact on the company. The document is structured as a formal announcement with tables of investment details and risk disclosures. It does not contain comprehensive financial statements or detailed financial performance data typical of annual or interim reports. It is not a transcript, audit report, or management discussion. The document is a regulatory announcement about financing activity related to cash management investments. Therefore, it fits best under Capital/Financing Update (CAP). The document length is about 5985 characters, which is sufficient for a detailed announcement but not a full financial report. Hence, the classification is CAP with high confidence.
2023-09-05 Chinese
关于使用自有资金收购海南惠海医药100%股权的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by a company about its decision to use its own funds to acquire 100% equity of another company. It details the transaction parties, the investment amount, the basic information of the target company, financial data, and the impact of the acquisition. There is no indication that this is a full annual or interim report, audit report, or earnings release. The document is focused on a capital investment transaction, specifically an acquisition of equity. It is not a merger or tender offer filing but rather a capital/financing update related to the company's investment activities. The document length is about 3,146 characters, which is consistent with an announcement rather than a full report. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2023-09-01 Chinese
独立董事关于控股股东及其他关联方占用公司资金、公司对外担保情况的专项说明和独立意见
Regulatory Filings Classification · 95% confidence The document is an independent director's special statement and opinion regarding the company's external guarantees and related party fund occupation during the reporting period. It references compliance with various Chinese securities regulations and company laws, and discusses the absence of non-operating fund occupation by controlling shareholders and external guarantees issues. The document is a regulatory compliance statement rather than a full financial report or audit. It does not contain financial statements or detailed financial data, nor is it a meeting presentation or voting result. It fits best under Regulatory Filings (RNS) as a compliance disclosure related to governance and regulatory requirements.
2023-08-24 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.